HLX43
HLX43 is an antibody-drug conjugate (ADC) targeting PD-L1. HLX43 is promising for research of PD-L1-positive solid tumors (e.g., NSCLC, head and neck cancer) [1][2].
Product Specifications
UNSPSC
12352005
Target
Antibody-Drug Conjugates (ADCs) ; PD-1/PD-L1
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
97.73
Smiles
[HLX43]
Molecular Weight
153714 (average)
References & Citations
[1]Wang J, et al. A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced/metastatic solid tumors[J]. 2025.|[2]Shan YQ, et al. Anti-pdl1 antibody-drug conjugate and use. WO2024230755A1. 2024-11-14.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
